Vinva Investment Management Ltd Sells 10,085 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Vinva Investment Management Ltd cut its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 34.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,524 shares of the biotechnology company's stock after selling 10,085 shares during the quarter. Vinva Investment Management Ltd's holdings in United Therapeutics were worth $6,983,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $25,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the third quarter valued at $33,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp grew its stake in shares of United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in United Therapeutics in the fourth quarter valued at $131,000. 94.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $929,678.52. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the company's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,255 shares of company stock valued at $32,614,521 in the last three months. 11.90% of the stock is currently owned by insiders.

Remove Ads

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $0.61 during midday trading on Friday, hitting $312.99. 1,155,261 shares of the company's stock were exchanged, compared to its average volume of 446,848. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The company has a market cap of $14.06 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The stock has a 50 day moving average price of $345.10 and a 200-day moving average price of $357.02.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the firm earned $4.36 earnings per share. On average, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.